Acute promyelocytic leukemia is characterized by the rearrangement of the retinoic acid receptor alpha (RARA) gene and its fusion with other genes. We report a novel case of variant acute promyelocytic leukemia with the karyotype der(2)t(2;17)(q32;q21). Array comparative genomic hybridization revealed distinct chromosome breakpoints within the RARA and oligonucleotide/oligosaccharide-binding fold containing 2A (OBFC2A) genes. Sequence analysis of the OBFC2A/RARA transcript showed that exon 5 of OBFC2A was fused with exon 3 of RARA through the same breakpoint as in previously described fusions of RARA.
Introduction
Rearrangement of the retinoic acid receptor alpha (RARA) gene and fusion with the gene encoding promyelocytic leukemia protein (PML) has been reported as a cause of acute promyelocytic leukemia (APL). 1,2 PML/RARA fusion causes reduced transcriptional activation, inhibition of myeloid differentiation, and APL. 3 All-trans retinoic acid (ATRA) effectively reverses this and is used in induction therapy of APL. However, in APL variants RARA is fused with genes other than PML, such as promyelocytic leukemia zinc finger (PLZF), 4 nucleophosmin (NPM1), 5 nuclear mitotic apparatus (NUMA1), 6 signal transducer and activator of transcription 5b (STAT5B), 7 cAMP-dependent protein kinase type I-alpha regulatory subunit (PRKAR1A), 8 FIP1-like 1 (FIP1L1), 9 or BCL6 corepressor (BCOR). 10 Unlike other forms, variant APL associated with STAT5B/RARA or PLZF/RARA are resistant to ATRA. 7, 11 This study reports a patient with variant APL due to a novel RARA gene rearrangement involving the oligonucleotide/oligosaccharide-binding fold containing 2A (OBFC2A) gene.
The OBFC2A gene located at chromosome 2q32.3 encodes human single-stranded DNA binding protein 2 (hSSB2 or OBFC2A), which plays a role in DNA damage response and genomic stability. 12, 13 To our knowledge, this is the first report showing involvement of the OBFC2A gene in a human disease.
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Methods

Case report
A 59-year-old man was transferred to our hospital with night sweats over the previous month, blood-tinged sputum, and petechia for 10 days. Laboratory investigations showed following: Hb level, 7.8 g/dL; platelet count, 41×10 3 /mm 3 ; leukocyte count, 96.9×10 3 /mm 3 (61% blasts and abnormal promyelocytes) ( Figure 1A 
Chromosome analysis and FISH
A BM sample was processed after short-term (24 hours), unstimulated culture following standard procedures. Chromosomes were G-banded, and the karyotype was interpreted according to the International System for Human Cytogenetic Nomenclature 2009. FISH analysis was performed using a PML/RARA dual-color dual fusion translocation probe (Vysis) and a RARA dual-color break-apart probe (Vysis). All analyses were performed after obtaining written informed consent from the patient.
Array CGH analysis
High-resolution oligonucleotide array comparative genomic hybridization (CGH) was performed using the Whole Human Genome CGH microarray Kit 244K (Agilent Technologies) (GEO accession number: GSE42984). Genomic DNA was labeled and hybridized to the array according to the manufacturer's protocol. Genomic imbalances were analyzed by the Genomic Workbench Standard Edition 5.0 (Agilent Technologies). Probes in the boundaries of copy number changes in chromosomes 2 and 17 were detected, and their position information was obtained from the manufacturer's sequence list for designing specific primers for fusion gene RT-PCR.
RT-PCR and sequencing for fusion transcript
Total RNA was extracted from BM aspirate at presentation and reverse transcribed into cDNA with random hexamers. OBFC2A/RARA mRNA was amplified with the following 
In vitro ATRA treatment and morphologic assessment
Differentiation effects of ATRA were examined in NB4, HL60, and leukemic cells of the patient, according to the methodology used in a previous study. 14
Results and Discussion
The karyotype of BM cells showed clonal der (2) FISH analysis showed an extra RARA signal with the PML/RARA probe and a 3′ RARA green signal with the RARA break-apart probe on der(2) (Figure 2A ).
Array CGH analysis to identify the exact region of rearrangement defined a loss in 2q32.3-qter and a gain in 17q21.2-qter. The breakpoints were located within the OBFC2A gene in 2q32.3 and the RARA gene in 17q21.2 ( Figure 2B ). To confirm the presence of OBFC2A/RARA fusion transcript, we performed RT-PCR using primers specific for OBFC2A and RARA. The predicted 281-bp product was specifically amplified from the patient's cDNA ( Figure 2C ). Direct sequence analysis showed that the RARA portion of the transcript started in exon 3 and was fused in-frame to exon 5 of OBFC2A ( Figure 2D ). As a result, the OBFC2A 5′-region encoding the DNA-binding domain (DBD) was fused to the 3′-For personal use only. on October 28, 2017. by guest www.bloodjournal.org From region of RARA, which includes the DBD and ligand-binding domain (LBD) ( Figure 2E ).
The OBFC2A/RARA fusion gene is predicted to encode a 551-amino acid protein.
The OBFC2A gene consists of 7 exons spanning 10.4 kb and ubiquitously encodes a protein component of the heterotrimeric complex SOSS (sensor of single-stranded DNA).
SOSS complexes maintain genome stability via DNA damage-response pathways, particularly homologous recombination-dependent repair of DNA double-strand breaks. 12, 13 It is noteworthy that PML also supports DNA double-strand break repair by homologous recombination. 15 The OBF2CA protein is characterized by an N-terminal oligonucleotide/oligosaccharide-binding fold (OB fold) that binds to single-stranded DNA substrate, followed by an unstructured proline/glycine-rich tail region. 16 Most of this tail region is deleted in the fusion protein, but the OB fold is retained, providing the possibility of dimerization of the OBFC2A/RARA fusion protein through the OB fold. 17 RARA functions by binding as a heterodimer with retinoid X receptor (RXR) to retinoic acid response elements (RARE). 3 This RARA-RXR complex is required for the promyelocyte differentiation process. Binding of retinoic acid (RA) to RAR results in a conformational change in the heterodimer, allowing release of co-repressors, recruitment of co-activators, and consequently, gene expression. RARA fusion proteins strongly bind to corepressors and requires a pharmacological dose of RA to release co-repressors and recruit coactivators. RA degrades the PML-RARA fusion protein through proteosome-mediated pathways and caspases. 18, 19 As in all other RARA fusion proteins, OBFC2A/RARA contains the DBD and LBD domains of RARA. [4] [5] [6] [7] [8] [9] 20 The OBFC2A/RARA fusion protein is expected to produce the same biological effects as those mediated by PML/RARA. It might be a dominant negative mutant for OBFC2A and promote tumor formation. Variant APL with For personal use only. on October 28, 2017. by guest www.bloodjournal.org From OBFC2A/RARA fusion gene appeared to be sensitive to ATRA by in vitro assay ( Figure 1B) , although on day 14, there was early morphological features of differentiation in the bone marrow because of the discontinuation of ATRA for 7 days.
To summarize, we report a patient with a novel OBFC2A/RARA fusion gene that gives rise to ATRA-sensitive variant APL. Additional studies on the OBFC2A/RARA fusion are required to understand its mechanism of leukemogenesis. Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly by the American Society of For personal use only. on October 28, 2017. by guest www.bloodjournal.org From
